New AI-generated COVID drug enters Phase I clinical trials: ‘Effective against all variants’
Artificial intelligence is increasingly moving into the health care arena and helping to streamline medical processes — including the creation of new drugs. Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed drug for COVID-19 has entered Phase I clinical trials. This oral…